Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010845 | 0.95 | HSD11B1 (0.49) | HSD11B1TSHRKMT2APOLBSMN1; SMN2 | |
| SCHEMBL4010849 | 0.95 | HSD11B1 (0.49) | HSD11B1TSHRKMT2APOLBSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL27664845 | 0.95 | HSD11B1 (0.50) | HSD11B1TSHRKMT2APOLBSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL612344 | 0.95 | HSD11B1 (0.50) | HSD11B1TSHRKMT2APOLBSMN1; SMN2 | |
| SCHEMBL27684790 | 0.89 | HSD11B1 (0.63) | HSD11B1TSHRKMT2APOLBSMN1; SMN2 | |
| SCHEMBL612865 | 0.89 | HSD11B1 (0.63) | HSD11B1TSHRKMT2APOLBSMN1; SMN2 | |
| SCHEMBL4009615 | 0.84 | HSD11B1 (0.56) | HSD11B1TSHRKMT2APOLBSMN1; SMN2 | |
| SCHEMBL4009624 | 0.84 | HSD11B1 (0.56) | HSD11B1TSHRKMT2APOLBSMN1; SMN2 | |
| SCHEMBL612099 | 0.81 | HSD11B1 (0.53) | HSD11B1TSHRKMT2APOLBSMN1; SMN2 | |
| SCHEMBL612098 | 0.81 | HSD11B1 (0.53) | HSD11B1TSHRKMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | claimed |
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, CYP11B1, HSD3B1 | HSD11B1 1/4885TSHR 1143/4885KMT2A 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.